Generation Bio (GBIO)
(Real Time Quote from BATS)
$3.25 USD
+0.18 (5.86%)
Updated Jul 25, 2024 10:40 AM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GBIO 3.25 +0.18(5.86%)
Will GBIO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GBIO
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates
GBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
Generation Bio Co. (GBIO) Reports Q1 Loss, Misses Revenue Estimates
Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio
Other News for GBIO
Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Generation Bio (GBIO), LAVA Therapeutics (LVTX) and Aura Biosciences Inc (AURA)
Wall Street Analysts Are Bullish on Top Healthcare Picks
12 Health Care Stocks Moving In Tuesday's Intraday Session
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Generation Bio (GBIO)